Alan Wade

2.9k total citations
68 papers, 2.2k citations indexed

About

Alan Wade is a scholar working on Experimental and Cognitive Psychology, Pharmacology and Psychiatry and Mental health. According to data from OpenAlex, Alan Wade has authored 68 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Experimental and Cognitive Psychology, 29 papers in Pharmacology and 17 papers in Psychiatry and Mental health. Recurrent topics in Alan Wade's work include Treatment of Major Depression (26 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (17 papers) and Mental Health Research Topics (16 papers). Alan Wade is often cited by papers focused on Treatment of Major Depression (26 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (17 papers) and Mental Health Research Topics (16 papers). Alan Wade collaborates with scholars based in United Kingdom, Denmark and United States. Alan Wade's co-authors include G. Crawford, Nava Zisapel, Tali Nir, Ole Lemming, Henning Friis Andersen, Ulla Lepola, Ian Ford, Moshe Laudon, Hannu Koponen and Alex McConnachie and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and The British Journal of Psychiatry.

In The Last Decade

Alan Wade

66 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan Wade United Kingdom 27 1.0k 797 537 485 411 68 2.2k
Cláudio N. Soares Canada 42 755 0.7× 416 0.5× 408 0.8× 426 0.9× 235 0.6× 148 5.4k
Alain Patat France 28 545 0.5× 416 0.5× 633 1.2× 501 1.0× 142 0.3× 125 2.3k
Miriam Adelson Israel 29 368 0.4× 526 0.7× 341 0.6× 319 0.7× 99 0.2× 113 2.9k
Hannah Zuckerman Canada 18 440 0.4× 450 0.6× 309 0.6× 262 0.5× 67 0.2× 25 1.8k
M. Ansseau Belgium 23 417 0.4× 302 0.4× 298 0.6× 431 0.9× 242 0.6× 109 2.2k
Mohammad Alsuwaidan Canada 22 415 0.4× 552 0.7× 319 0.6× 881 1.8× 68 0.2× 37 2.2k
Michael Philipp Germany 22 664 0.6× 654 0.8× 335 0.6× 845 1.7× 56 0.1× 82 2.2k
Einat Peles Israel 28 348 0.3× 400 0.5× 328 0.6× 241 0.5× 122 0.3× 109 2.6k
Robert Pohl United States 28 975 0.9× 278 0.3× 360 0.7× 454 0.9× 55 0.1× 99 2.7k
Young Sup Woo South Korea 22 235 0.2× 416 0.5× 197 0.4× 858 1.8× 139 0.3× 132 1.7k

Countries citing papers authored by Alan Wade

Since Specialization
Citations

This map shows the geographic impact of Alan Wade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Wade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Wade more than expected).

Fields of papers citing papers by Alan Wade

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Wade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Wade. The network helps show where Alan Wade may publish in the future.

Co-authorship network of co-authors of Alan Wade

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Wade. A scholar is included among the top collaborators of Alan Wade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Wade. Alan Wade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wade, Alan, G. Crawford, David Young, Stephen L. Corson, & Colin Brown. (2019). Comparison of diclofenac gel, ibuprofen gel, and ibuprofen gel with levomenthol for the topical treatment of pain associated with musculoskeletal injuries. Journal of International Medical Research. 47(9). 4454–4468. 10 indexed citations
2.
Brodie, Martin J., Steve Chung, Alan Wade, et al.. (2015). Clobazam vs. Clonazepam for Adults with Epilepsy: Long-Term Results from a UK Primary Care Database (P1.257). Neurology. 84(14_supplement). 3 indexed citations
3.
Mancini, Michele, Alan Wade, Giulio Perugi, Alan Lenox‐Smith, & Alexander Schacht. (2014). Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants. Journal of Psychiatric Research. 51. 21–29. 26 indexed citations
4.
Wade, Alan, et al.. (2012). A survey of patient preferences for a placebo orodispersible tablet. Patient Preference and Adherence. 6. 201–201. 8 indexed citations
5.
Wade, Alan, et al.. (2010). A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support. International Clinical Psychopharmacology. 25(5). 288–296. 33 indexed citations
6.
7.
Wade, Alan, P. Johnson, & Alex McConnachie. (2010). Antidepressant treatment and cultural differences - a survey of the attitudes of physicians and patients in Sweden and Turkey. BMC Family Practice. 11(1). 93–93. 5 indexed citations
8.
Byford, Sarah, Barbara Barrett, Nicolas Despiégel, & Alan Wade. (2010). Impact of Treatment Success on Health Service Use and Cost in Depression. PharmacoEconomics. 29(2). 157–170. 35 indexed citations
9.
Kilts, Clinton D., Alan Wade, Henning Friis Andersen, & Thomas E. Schläepfer. (2009). Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opinion on Pharmacotherapy. 10(6). 927–936. 38 indexed citations
10.
Wade, Alan, Thomas E. Schläepfer, Henning Friis Andersen, & Clinton D. Kilts. (2008). Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of Psychiatric Research. 43(5). 568–575. 22 indexed citations
11.
Wade, Alan & Sue Downie. (2008). Prolonged-release melatonin for the treatment of insomnia in patients over 55 years. Expert Opinion on Investigational Drugs. 17(10). 1567–1572. 27 indexed citations
12.
Wade, Alan, José‐Luis Fernández, C. François, et al.. (2008). Escitalopram and Duloxetine in Major Depressive Disorder. PharmacoEconomics. 26(11). 969–981. 34 indexed citations
13.
Wade, Alan, et al.. (2007). A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Current Medical Research and Opinion. 23(7). 1605–1614. 85 indexed citations
14.
Bech, Per, Henning Andersen, & Alan Wade. (2006). Effective Dose of Escitalopram in ModerateversusSevere DSM-IV Major Depression. Pharmacopsychiatry. 39(4). 128–134. 35 indexed citations
15.
Wade, Alan. (2006). Closing the antidepressant efficacy gap between clinical trials and real patient populations. International Journal of Psychiatry in Clinical Practice. 10(sup3). 25–31.
16.
Lepola, Ulla, Alan Wade, & Henning Friis Andersen. (2004). Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. International Clinical Psychopharmacology. 19(3). 149–155. 76 indexed citations
17.
18.
Koponen, Hannu, Lotte Lauritzen, F. Rouillon, et al.. (2001). Prophylactic effect of citalopram in unipolar, recurrent depression. The British Journal of Psychiatry. 178(4). 304–310. 66 indexed citations
19.
Lepola, Ulla, Alan Wade, Esa Leìnonen, et al.. (1998). A Controlled, Prospective, 1-Year Trial of Citalopram in the Treatment of Panic Disorder. The Journal of Clinical Psychiatry. 59(10). 528–534. 82 indexed citations
20.
Wade, Alan. (1989). Pharmaceutical trials in psychiatric patients. BMJ. 298(6686). 1518.3–1518. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cláudio N. Soares Breakdown of academic impact, for papers by Alain Patat Breakdown of academic impact, for papers by Miriam Adelson Breakdown of academic impact, for papers by Hannah Zuckerman Breakdown of academic impact, for papers by M. Ansseau Breakdown of academic impact, for papers by Mohammad Alsuwaidan Breakdown of academic impact, for papers by Michael Philipp Breakdown of academic impact, for papers by Einat Peles Breakdown of academic impact, for papers by Robert Pohl Breakdown of academic impact, for papers by Young Sup Woo
Rankless by CCL
2026